---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000099"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:50:12.187689+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio Q2 net loss $11.2M; doses first patients in Phase 1 AML trial

## Summary
- Net loss of $11.2M ($2.45 per share) for Q2 2024; cash and equivalents $15.9M.
- R&D expenses rose to $9.2M (vs $6.9M YoY) on increased manufacturing costs.
- Phase 1 trial of SENTI-202 for AML now dosing; initial efficacy data expected by year-end 2024.
- Received $8M CIRM grant to support SENTI-202 clinical development.
- Regained Nasdaq minimum bid price compliance after 1-for-10 reverse stock split in July 2024.

## SEC filing metadata
- accession: 0001854270-24-000099
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000099/0001854270-24-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000099/snti-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000099
- JSON: https://secwatch.observer/filing/0001854270-24-000099.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.